Study of the Safety and Tolerability of AXA1665 in Subjects With Mild and Moderate Hepatic Insufficiency

Inclusion Criteria: * Willing to participate in the study and provide written informed consent * Male and female adults aged \> 18 years * Child-Pugh score ≤9 (i.e. Child-Pugh class A or B) * Liver Frailty Index (LFI) of ≥3.6 * Willing and able to engage in 30 minutes of walking/physical activity at least 3 days per week Exclusion Criteria: * Hospitalization for any complication of cirrhosis or taking new medications intended to treat hepatic encephalopathy within 2 months prior to Screening or any hospitalization for any cause/reason within 30 days prior to Screening * Prior history or presence of a transjugular intrahepatic portal systemic shunt (TIPS) * Current or history of significant alcohol consumption * Other poorly controlled medical condition \[e.g., renal disease with an estimated glomerular filtration rate (GFR) \<60 mL/min/1.73m2) * Known sensitivity and/or history of clinically significant food intolerance/allergies to proteins (including whey, soy, casein, amino acids, etc.) * Any extreme or unbalanced diet such as Ketogenic, Atkins, Paleo, Vegan, etc. * Unable or unwilling to adhere to contraception requirements * Any contraindications to a MRI scan * Any other condition that, in the opinion of the Investigator, renders the subject at risk for compliance, compromises the well-being of the subject, or hinders study completion